An interventional study of H.A.L.T. MAX spectacles in High Myopia, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Not yet recruiting. Open to participants aged 7 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center — 21 open to participants now, 22 under way, none of them phase 3. Myopia · Shanghai Eye Disease Prevention and Treatment Center.
Among the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, this one is the 25th largest by planned enrollment of the 36 interventional ones that give a count, is one of 10 that started in 2026, is one of 32 with no phase, reaches primary completion later than 21 of the 21 other live ones, and was the 42nd registered.
1,163 studies on the registry are indexed under Myopia; 227 are open to participants now.
Browse Myopia studies →21 of the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center are open now, in 1 country. Recruiting first, the newest first:
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 18–55
By country, each count listing its studies:
Of the 120 Myopia studies recruiting now, 19 (16%) set no upper age limit and 100 (83%) stop at 75 or younger; 84 take children under 18; 52 take healthy volunteers.
This study: 7 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 112 is above the median of 79 across 927 interventional studies indexed under Myopia.
Median enrollment 141 across the 36 interventional studies, 9,500 across the 6 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Eye Disease Prevention and Treatment Center is the lead sponsor of 67 studies on the registry; 31 are open to participants now.
9 of the studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05770661Shanghai Eye Disease Prevention and Treatment CenterChina Children Eye Study | 2026-12-31 |
| NCT07746804Shanghai Eye Disease Prevention and Treatment CenterSchool-based Myopia Prevention Trial for Children With Insufficient Hyperopic Reserve | 2027-06 |
| NCT07746752Shanghai Eye Disease Prevention and Treatment CenterSchool-based Myopia Prevention Trial for Children With Adequate Hyperopic Reserve | 2027-06 |
| NCT07746778Shanghai Eye Disease Prevention and Treatment CenterSchool-based Myopia Control Trial for Children With Premyopia or Myopia | 2027-06 |
| NCT07176949Shanghai Eye Disease Prevention and Treatment CenterEarly-Onset Myopia Intervention Project | 2027-06-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is intended to focus on children aged 7-14 years with high myopia and to use a 2-year, single-arm, prospective design in which participants wear H.A.L.T. MAX lenses for at least 12 hours per day for 2 consecutive years. By comparing changes in refractive error and other indicators, the study will evaluate the efficacy, safety, and wearing compliance of H.A.L.T. MAX lenses in delaying myopia progression in children with high myopia, thereby providing scientific evidence for public health efforts to delay myopia progression in highly myopic populations and for the formulation and implementation of programs to address the risk of blindness and visual impairment caused by high myopia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Wearing H.A.L.T. MAX spectacles for at least 12 hours a day over 2 years.
Device: H.A.L.T. MAX spectacles
Wearing H.A.L.T. MAX spectacles for at least 12 hours a day over 2 years.
SER change
The proportion of of the right eye SER change ≤ -1.50D after 2 year of intervention.
Time frame: 2 years
Axial change
The proportion of the right eye axial change ≥ 0.68 mm after 2 year of intervention.
Time frame: 2 years
Visual quality
Visual aquity
Time frame: 2 years
Adaptation outcome
Daily spectacles wearing time
Time frame: 2 years
Safety outcome
Occurrence of adverse events
Time frame: 2 years
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2029, 30 months later.
Of 200 non-industry interventional studies with no phase under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 30 months is above that.
Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Eye Disease Prevention and Treatment Center